Ergoteles LLC Sarepta Therapeutics, Inc. Transaction History

Ergoteles LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $1.26 Million - $1.87 Million	-11,873 Reduced 33.56%	23,502 $2.69 Million
Q1 2023 May 10, 2023	SELL	$117.53 - $155.99 $2.88 Million - $3.83 Million	-24,545 Reduced 40.96%	35,375 $4.88 Million
Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $5.11 Million - $6.69 Million	50,632 Added 545.13%	59,920 $7.76 Million
Q3 2022 Nov 14, 2022	SELL	$75.71 - $119.24 $2.4 Million - $3.78 Million	-31,661 Reduced 77.32%	9,288 $1.03 Million
Q2 2022 Aug 12, 2022	BUY	$62.69 - $88.44 $2.57 Million - $3.62 Million	40,949 New	40,949 $3.07 Million
Q1 2022 May 13, 2022	SELL	$63.15 - $90.42 $470,467 - $673,629	-7,450 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $575,736 - $740,679	7,450 New	7,450 $671,000
Q3 2021 Nov 15, 2021	SELL	$65.97 - $92.48 $3.52 Million - $4.93 Million	-53,300 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$69.38 - $86.75 $3.7 Million - $4.62 Million	53,300 New	53,300 $4.14 Million
Q1 2021 May 12, 2021	SELL	$72.25 - $168.95 $2.94 Million - $6.87 Million	-40,686 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$125.56 - $178.74 $5.11 Million - $7.27 Million	40,686 New	40,686 $6.94 Million

528

85M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.79B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.